HER2 BATs represent a class of targeted HER2 tumor antigens, comprising both anti-CD3 and anti-Her2 bi-armed antibodies, and have been shown to elicit substantial immune responses against cancer cells (177). This evidence concerns the gene ERBB2 and cancer.